Leading commercialisation
Torsten Hombeck will take charge of the commercial activities and the general strategy of Promethera Biosciences. The Belgian cell therapy specialist appointed Hombeck as Chief Commercial and Strategy Officer.
Hombeck was Co-CEO and Chief Business Officer at Cytonet GmbH & Co KG, spokesperson, Co-CEO and Chief Financial Officer at Agennix AG and Chief Financial officer at GPC Biotech AG. He has extensive experience in clinical and commercial drug development, as well as with regulatory filings for various drug development product candidates and financings of private and public companies including IPOs and follow ons. He received an MBA and Ph.D. in finance from the European Business School University of Business and Law in Oestrich-Winkel, Germany.
Promethera also appointed Christof Hettich as new Chairman of the Board.
NOD-Proteindesign.Andreas Heddergott/TUM.jpg
Certest
Consilium